TEGSEDI is the first and only self-administered, subcutaneous treatment for the polyneuropathy of hereditary ATTR amyloidosis in adults. TEGSEDI binds to TTR mRNA to inhibit production of TTR protein.
Contact:
Charlie Sanclemente
Cell: 609-220-9710
E-mail - CSanclemente@akceatx.com
TEGSEDI Prescribing Information »
Featured Content
